8-K: Aclaris Therapeutics Sells Olumiant Royalties and Milestones for Up to $31.5 Million to OMERS

Aclaris Therapeutics has sold a portion of its future royalty payments and milestone rights for Olumiant to OMERS for an upfront payment of $26.5 million, with potential for an additional $5 million based on sales milestones.

Summary

• Aclaris Therapeutics has entered into an agreement with OMERS, selling a portion of its future royalty payments and remaining anniversary milestones related to the drug Olumiant for the treatment of alopecia areata.
• The deal involves an upfront payment of $26.5 million to Aclaris.
• Aclaris is eligible to receive up to an additional $5.0 million based on the achievement of certain sales milestones for Olumiant in 2024.
• OMERS has acquired a portion of the royalty payable by Eli Lilly to Aclaris for worldwide net sales of Olumiant for alopecia areata from April 1, 2024, through the remainder of the royalty term.
• OMERS also acquired 100% of the remaining anniversary milestone payments payable by Lilly to Aclaris under the license agreement.
• The transaction is intended to strengthen Aclaris' balance sheet and provide financial flexibility to pursue strategic opportunities.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the non-dilutive funding and increased financial flexibility, but tempered by the fact that the company is selling future revenue streams and is dependent on the success of another company's product.

Positives

• The transaction provides Aclaris with a significant upfront payment of $26.5 million.
• Aclaris has the potential to receive an additional $5.0 million based on sales milestones.
• The deal strengthens Aclaris' balance sheet and provides enhanced financial flexibility.
• The transaction is non-dilutive, meaning it does not dilute existing shareholders' ownership.
• The funds will support Aclaris' strategic priorities and internal programs.

Risks

• The potential for the additional $5.0 million payment is contingent on the achievement of specific sales milestones for Olumiant in 2024.
• Aclaris is now dependent on the success of Olumiant sales by Eli Lilly to receive the milestone payments.
• The company is still subject to risks and uncertainties inherent in clinical trials and reliance on third parties.

Future Outlook

Aclaris intends to use the proceeds from this transaction to support its strategic priorities, invest in internal programs, and pursue other value-creating opportunities. The company is also undergoing a strategic review of its business.

Management Comments

• Dr. Neal Walker, Interim President & CEO and Chair of the Board of Directors of Aclaris, stated that the transaction bolsters their balance sheet and provides enhanced financial flexibility.
• Dr. Walker also mentioned that they will continue to pursue opportunities to invest in programs that complement and enhance their existing drug development pipeline.

Industry Context

This transaction is an example of a biopharmaceutical company monetizing its royalty streams to secure non-dilutive funding. This is a common strategy in the industry to fund research and development activities without diluting existing shareholders. OMERS Life Sciences is a known investor in this space.

Comparison to Industry Standards

• Royalty monetization is a common practice in the biopharmaceutical industry, with companies like Royalty Pharma being major players in this space.
• Similar deals often involve upfront payments and milestone payments based on sales performance.
• The valuation of royalty streams depends on factors such as the drug's market potential, remaining patent life, and the terms of the underlying license agreement.
• Compared to other royalty deals, the $31.5 million potential value for Aclaris is relatively modest, suggesting that the Olumiant royalty stream may not be as large as some other blockbuster drugs.
• Companies like Ligand Pharmaceuticals and XOMA have also engaged in similar royalty monetization strategies.

Stakeholder Impact

• Shareholders will benefit from the strengthened balance sheet and increased financial flexibility.
• Employees may benefit from the continued investment in internal programs.
• Customers may benefit from the continued development of new treatments.
• Creditors may view the company as less risky due to the improved financial position.

Next Steps

• Aclaris will use the funds to support its strategic priorities and internal programs.
• Aclaris will continue its strategic review of its business.
• The company intends to file the full agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.

Key Dates

Keywords

Aclaris Therapeutics, OMERS, Olumiant, Royalty Sale, Milestone Payments, Alopecia Areata, Eli Lilly, Non-Dilutive Financing, Biopharmaceutical, Immunoinflammatory Diseases